company traded as nasdaq cprx industry biotechnology headquarters coral gables fl united states key people patrick j. mcenany co founder chairman president and chief executive officer products in development revenue us 0 million 2014 1 operating income us 15.5 million 2014 1 total assets us 43.9 million 2014 1 total equity us 35.2 million 2014 1 number of employees 20 as of march 20 2015 1 website www.catalystpharma.com footnotes references 2 3 catalyst pharmaceuticals is a biopharmaceutical company based in coral gables florida . the company is developing therapeutics for rare neurological diseases including firdapse 3 4 diaminopyridine phosphate a potassium channel blocker for the treatment of lambert eaton myasthenic syndrome lems and cpp 115 a gaba transaminase for the treatment of infantile spasms . 4 5 contents 1 history 2 business development 3 product candidates 4 controversies 5 references history edit founded in 2002 catalyst pharmaceuticals competed an ipo in 2006 . 6 catalyst focused primarily on developing therapies to prevent addiction until 2012 . 4 business development edit in 2009 catalyst pharmaceuticals in licensed worldwide rights to a family of gaba inhibitors including cpp 115 from northwestern university . 7 8 catalyst pharmaceuticals in licensed the right to develop firdapse for the north american market from biomarin in 2012 . 9 product candidates edit catalyst pharmaceuticals obtained a breakthrough therapy designation for firdapse from the fda for the development of a treatment of patients suffering from lems in 2013 . 10 11 catalyst pharmaceuticals has evaluated firdapse for safety and efficacy in clinical trials . 12 13 14 15 16 17 although not approved by the fda as of 2015 firdapse is available to eligible lems patients through an expanded access program . 18 19 20 firdapse is also being evaluated as a potential therapy for patients with congenital myasthenic syndromes for which it has obtained an orphan drug designation from the fda . 21 22 23 catalyst pharmaceuticals is also developing cpp 115 as a treatment for infantile spasms . 24 25 controversies edit the development of firdapse by catalyst pharmaceuticals has brought attention to orphan drug policies that grant market exclusivity as an incentive for companies to develop therapies for small numbers of patients . 4 26 27 references edit a b c d e catalyst pharmaceuticals 2014 annual report form 10 k xbrl . retrieved 2015 03 05 . united states securities and exchange commission . catalyst pharmaceuticals cprx stock information via wikinvest . catalyst pharmaceuticals cprx annual sec balance sheet filing via wikinvest . a b c mann jr. joseph a. the big gamble catalyst pharmaceuticals of coral gables bets on new drug for rare disease miami herald 18 july 2015 . retrieved on 26 august 2015 . nehamas nicholas . catalyst pharmaceuticals reports second quarter net loss plans to submit new drug for fda approval miami herald 11 august 2015 . retrieved on 26 august 2015 . catalyst pharmaceuticals registration statement form s 1 xbrl . retrieved 2015 09 08 . united states securities and exchange commission . hawker d. and r. silverman . synthesis and evaluation of novel heteroaromatic substrates of gaba aminotransferase bioorganic & medicinal chemistry 1 october 2012 . retrieved on 8 september 2015 . brian bandell . catalyst pharmaceutical signs licensing deal with northwestern south florida business journal 31 august 2009 . retrieved on 8 september 2015 . catalyst acquires late stage orphan drug from biomarin genetic engineering and biotechnology news 1 november 2012 . retrieved on august 27 2015 . burrill and co. first eight months of 2013 boast strong m & a financing totals drug discovery news october 2013 . retrieved on 26 august 2015 . firdapse amifampridine regulatory update biocentury 17 august 2015 . retrieved on 3 september 2015 . subscription required manocha vrinda . catalyst pharma says autoimmune disorder drug safe for heart reuters 8 january 2014 . retrieved on 26 august 2015 . powers marie . firdapse cardiac safety study hits endpoint ; lems data next bioworld 9 january 2014 . retrieved on 26 august 2015 . subscription required brief catalyst pharmaceuticals announces positive top line phase 3 data from firdapse clinical trial reuters 29 september 2014 . retrieved on 26 august 2015 . catalyst s firdapse meets in lems phase iii biocentury 29 september 2014 . retrieved on 26 august 2015 . subscription required oh shin et al. amifampridine phosphate firdapsetm is safe and effective in a pivotal phase 3 trial in lems patients neurology april 24 2015 . retrieved on 27 august 2015 . lems firdapse study shows encouraging results muscular dystrophy association 29 september 2014 . retrieved on 26 august 2015 . radke james . catalyst using the expanded access program to conduct phase iv study with lems patients rare disease report 30 october 2014 . retrieved on 25 august 2015 . levinsohn ben . five biotech stocks for the next six months barron s stocks to watch blog 17 june 2015 . retrieved on 27 august 2015 . young donna . catalyst steps up to provide lems patients expanded firdapse access scrip intelligence 24 april 2014 . retrieved on 28 september 2014 . subscription required orphan drug designations and approvals us food and drug administration 3 march 2015 . retrieved on 26 august 2015 . ampel celia . catalyst pharma stock rises 5 % after firm hits fda milestone south florida business journal 5 march 2015 . retrieved on 26 august 2015 . mazell shawnay et al. clinical and jitter changes during oral amifampridine phosphate firdapse treatment in congenital myasthenic syndrome american association of neuromuscular & electrodiagnostic medicine 2015 annual meeting abstract 169 1 june 2015 . retrieved on 8 september 2015 . briggs sw et al. cpp 115 a vigabatrin analogue decreases spasms in the multiple hit rat model of infantile spasms epilepsia . january 2014 . retrieved on 8 september 2015 . orphan drug designations and approvals us food and drug administration 15 september 2015 . retrieved on 8 september 2015 . drummond michael and towse adrian . orphan drugs policies a suitable case for treatment the european journal of health economics may 2014 . retrieved on 3 september 2015 . lowe derek . market exclusivity is sometimes too much seeking alpha 27 april 2015 . retrieved on 8 september 2015 . retrieved from https en.wikipedia.org w index.php title catalyst pharmaceuticals & oldid 729867801 categories companies in the nasdaq biotechnology indexbiotechnology companies of the united statescompanies listed on nasdaqpharmaceutical companies established in 2002orphan drug companiescompanies based in miami dade county florida navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 15 july 2016 at 03 31 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view